nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation
|
Hemant Kumar, S |
|
|
29 |
11 |
p. |
artikel |
2 |
Application of proteomics for novel drug discovery and risk prediction optimisation in stroke and myocardial infarction: a review of in-human studies
|
Webb, Richard J. |
|
|
29 |
11 |
p. |
artikel |
3 |
Beyond resmetirom approval for NAFLD: what has to be done?
|
Ezhilarasan, Devaraj |
|
|
29 |
11 |
p. |
artikel |
4 |
Clinical strategies with antibody–drug conjugates as potential modifications for virotherapy
|
Liao, Zi-Xian |
|
|
29 |
11 |
p. |
artikel |
5 |
Collaborative GSK–University of Strathclyde doctoral research and training programmes: Transforming approaches to industry–academia engagement
|
Paterson, Laura C. |
|
|
29 |
11 |
p. |
artikel |
6 |
Contents page
|
|
|
|
29 |
11 |
p. |
artikel |
7 |
Data-driven toxicity prediction in drug discovery: Current status and future directions
|
Wang, Ningning |
|
|
29 |
11 |
p. |
artikel |
8 |
Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges
|
Wang, Yuxuan |
|
|
29 |
11 |
p. |
artikel |
9 |
3D light-sheet fluorescence microscopy in preclinical and clinical drug discovery
|
Roostalu, Urmas |
|
|
29 |
11 |
p. |
artikel |
10 |
Downregulation of microRNA-29b in cancer and fibrosis: molecular insights and clinical implications
|
Shinde, Pratik Pramod |
|
|
29 |
11 |
p. |
artikel |
11 |
Drug discovery and development in idiopathic pulmonary fibrosis: the changing landscape
|
Cruwys, Simon |
|
|
29 |
11 |
p. |
artikel |
12 |
Early career researchers’ experiences in drug discovery in Africa
|
Mayoka, Godfrey |
|
|
29 |
11 |
p. |
artikel |
13 |
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis
|
Antunes, Stella S. |
|
|
29 |
11 |
p. |
artikel |
14 |
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
|
Hu, Lingrong |
|
|
29 |
11 |
p. |
artikel |
15 |
From promise to progress: the dynamic landscape of glioblastoma immunotherapy
|
Ijaz, Muhammad |
|
|
29 |
11 |
p. |
artikel |
16 |
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections
|
Bhat, Mohammad Faizan |
|
|
29 |
11 |
p. |
artikel |
17 |
MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer
|
Pulous, Fadi E. |
|
|
29 |
11 |
p. |
artikel |
18 |
MicroRNAs and therapeutic potentials in acute and chronic cardiac disease
|
Song, Rui |
|
|
29 |
11 |
p. |
artikel |
19 |
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases
|
Madhubala, Dev |
|
|
29 |
11 |
p. |
artikel |
20 |
P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators
|
Guo, Yang |
|
|
29 |
11 |
p. |
artikel |
21 |
Promising therapeutic targets for tumor treatment: Cleaved activation of receptors in the nucleus
|
Fu, Mengdie |
|
|
29 |
11 |
p. |
artikel |
22 |
Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches
|
de Jong, Amos J. |
|
|
29 |
11 |
p. |
artikel |
23 |
Spotlight on HIV-derived TAT peptide as a molecular shuttle in drug delivery
|
Maani, Zahra |
|
|
29 |
11 |
p. |
artikel |
24 |
Targeted protein degradation: current molecular targets, localization, and strategies
|
Pliatsika, Dimanthi |
|
|
29 |
11 |
p. |
artikel |
25 |
The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements
|
Fernald, Kenneth D.S. |
|
|
29 |
11 |
p. |
artikel |
26 |
The regulatory mechanism of natural polysaccharides in type 2 diabetes mellitus treatment
|
Bo, Surina |
|
|
29 |
11 |
p. |
artikel |
27 |
Unveiling the macrophage dynamics in osteoarthritic joints: From inflammation to therapeutic strategies
|
Gaigeard, Nicolas |
|
|
29 |
11 |
p. |
artikel |
28 |
Unveiling the potential of molecular imprinting polymer-based composites in the discovery of advanced drug delivery carriers
|
Kumar, Amit |
|
|
29 |
11 |
p. |
artikel |
29 |
Utilization of phase I studies for target validation of first-in-class drugs
|
Kawabe, Yoshiki |
|
|
29 |
11 |
p. |
artikel |
30 |
Which cryptic sites are feasible drug targets?
|
Lazou, Maria |
|
|
29 |
11 |
p. |
artikel |